Keith Miller, MD
Cardiovascular Disease · Lincoln, NENPI 1295849602
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $77,385 of the $86,180 with a category attached, or 89.8%. 15 manufacturers reported payments, led by Boehringer Ingelheim at 59.5% of the total. Among cardiovascular disease clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 137 payments — averaging $629.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$51K
- Lilly USA, LLC$34K
- Novo Nordisk$161
- Abbott$151
- Medtronic$124
- Pfizer$91
- plus $354 from 9 others
Across 493 payments — averaging $239.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$72K
- Amgen$46K
What the payments were for
- Consulting fees$3,7504%
- Speaking & faculty fees$77,38590%
- Travel & lodging$2,4503%
- Food & beverage$2,4343%
- Education$1610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 71 | $51,260 |
| Lilly USA, LLC | 35 | $34,040 |
| Novo Nordisk | 5 | $161 |
| Abbott | 1 | $151 |
| Medtronic | 3 | $124 |
| Pfizer | 5 | $91 |
| Amgen | 2 | $76 |
| Chiesi USA, Inc. | 3 | $71 |
| Heartflow, Inc. | 2 | $67 |
| E.r. Squibb & Sons, L.L.C. | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Novartis | 2 | $30 |
| Scpharmaceuticals Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $11 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$84,039
- AMPLATZER Occluders$151
How this compares
$86,180 in reported general payments places this provider in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 726 | $565,917 |
| XareltoRivaroxaban | 426 | $375,939 |
| JardianceEmpagliflozin | 374 | $336,273 |
| OzempicSemaglutide | 229 | $234,904 |
| Repatha SureclickEvolocumab | 251 | $199,719 |
| FarxigaDapagliflozin Propanediol | 219 | $151,454 |
| EntrestoSacubitril/Valsartan | 137 | $117,322 |
| TrulicityDulaglutide | 101 | $101,194 |
| Praluent PenAlirocumab | 102 | $52,153 |
| MultaqDronedarone Hcl | 31 | $28,634 |
| MounjaroTirzepatide | 17 | $18,325 |
| Metoprolol Succinate | 780 | $10,272 |
| Nebivolol Hcl | 183 | $9,871 |
| VascepaIcosapent Ethyl | 18 | $9,433 |
| Ezetimibe | 478 | $8,250 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $91 | $565,917726 claims |
| Boehringer IngelheimJardiance, Tradjenta | $51,260 | $342,419385 claims |
| Novo NordiskOzempic | $161 | $234,904229 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $34,040 | $119,518118 claims |
| NovartisEntresto | $30 | $117,322137 claims |
| Sanofi-aventis U.S. LLCMultaq | $33 | $28,63431 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 97 cardiovascular disease providers in Nebraska.
Other cardiovascular disease in Lincoln
- Robert PercellLincoln$918K
- Steven KruegerLincoln$388K
- Wynn HunterLincoln$46K
- Gina MentzerLincoln$27K
- Rajeev AnchanLincoln$7K
- Kaliprasad AyalaLincoln$5K
- John SteuterLincoln$4K
- Rebecca RundlettLincoln$3K
- Omar NassLincoln$3K
- Chad TraversLincoln$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.